Literature DB >> 16825336

A universal vaccine for serogroup B meningococcus.

Marzia M Giuliani1, Jeannette Adu-Bobie, Maurizio Comanducci, Beatrice Aricò, Silvana Savino, Laura Santini, Brunella Brunelli, Stefania Bambini, Alessia Biolchi, Barbara Capecchi, Elena Cartocci, Laura Ciucchi, Federica Di Marcello, Francesca Ferlicca, Barbara Galli, Enrico Luzzi, Vega Masignani, Davide Serruto, Daniele Veggi, Mario Contorni, Maurizio Morandi, Alessandro Bartalesi, Vanda Cinotti, Donatella Mannucci, Francesca Titta, Elisa Ovidi, Jo Anne Welsch, Dan Granoff, Rino Rappuoli, Mariagrazia Pizza.   

Abstract

Meningitis and sepsis caused by serogroup B meningococcus are two severe diseases that still cause significant mortality. To date there is no universal vaccine that prevents these diseases. In this work, five antigens discovered by reverse vaccinology were expressed in a form suitable for large-scale manufacturing and formulated with adjuvants suitable for human use. The vaccine adjuvanted by aluminum hydroxide induced bactericidal antibodies in mice against 78% of a panel of 85 meningococcal strains representative of the global population diversity. The strain coverage could be increased to 90% and above by the addition of CpG oligonucleotides or by using MF59 as adjuvant. The vaccine has the potential to conquer one of the most devastating diseases of childhood.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825336      PMCID: PMC2047628          DOI: 10.1073/pnas.0603940103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms.

Authors:  M C Maiden; J A Bygraves; E Feil; G Morelli; J E Russell; R Urwin; Q Zhang; J Zhou; K Zurth; D A Caugant; I M Feavers; M Achtman; B G Spratt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

2.  Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from healthy carriers.

Authors:  D A Caugant; K Bøvre; P Gaustad; K Bryn; E Holten; E A Høiby; L O Frøholm
Journal:  J Gen Microbiol       Date:  1986-03

3.  Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.

Authors:  P Olin; F Rasmussen; L Gustafsson; H O Hallander; H Heijbel
Journal:  Lancet       Date:  1997-11-29       Impact factor: 79.321

4.  Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C.

Authors:  P Costantino; S Viti; A Podda; M A Velmonte; L Nencioni; R Rappuoli
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

5.  Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.

Authors:  Nick Andrews; Ray Borrow; Elizabeth Miller
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

6.  Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity.

Authors:  Jo Anne Welsch; Gregory R Moe; Raffaella Rossi; Jeannette Adu-Bobie; Rino Rappuoli; Dan M Granoff
Journal:  J Infect Dis       Date:  2003-11-19       Impact factor: 5.226

7.  Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease.

Authors:  David J Litt; Silvana Savino; Amanda Beddek; Maurizio Comanducci; Colin Sandiford; Julia Stevens; Michael Levin; Cathy Ison; Mariagrazia Pizza; Rino Rappuoli; J Simon Kroll
Journal:  J Infect Dis       Date:  2004-09-09       Impact factor: 5.226

8.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

9.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  242 in total

Review 1.  Virulence determinants involved in differential host niche adaptation of Neisseria meningitidis and Neisseria gonorrhoeae.

Authors:  Stephanie Schielke; Matthias Frosch; Oliver Kurzai
Journal:  Med Microbiol Immunol       Date:  2010-04-09       Impact factor: 3.402

2.  Mapping of the Neisseria meningitidis NadA cell-binding site: relevance of predicted {alpha}-helices in the NH2-terminal and dimeric coiled-coil regions.

Authors:  Regina Tavano; Barbara Capecchi; Paolo Montanari; Susanna Franzoso; Oriano Marin; Maryta Sztukowska; Paola Cecchini; Daniela Segat; Maria Scarselli; Beatrice Aricò; Emanuele Papini
Journal:  J Bacteriol       Date:  2010-10-22       Impact factor: 3.490

Review 3.  Bacterial outer membrane vesicles in disease and preventive medicine.

Authors:  Can M Unal; Viveka Schaar; Kristian Riesbeck
Journal:  Semin Immunopathol       Date:  2010-12-12       Impact factor: 9.623

4.  Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined.

Authors:  Massimiliano Biagini; Marco Spinsanti; Gabriella De Angelis; Sara Tomei; Ilaria Ferlenghi; Maria Scarselli; Fabio Rigat; Nicola Messuti; Alessia Biolchi; Alessandro Muzzi; Giulia Anderloni; Brunella Brunelli; Elena Cartocci; Francesca Buricchi; Chiara Tani; Maria Stella; Monica Moschioni; Elena Del Tordello; Annalisa Colaprico; Silvana Savino; Marzia M Giuliani; Isabel Delany; Mariagrazia Pizza; Paolo Costantino; Nathalie Norais; Rino Rappuoli; Vega Masignani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-17       Impact factor: 11.205

5.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

6.  Population snapshot of invasive serogroup B meningococci in South Africa from 2005 to 2008.

Authors:  Mignon du Plessis; Chivonne Moodley; Kedibone M Mothibeli; Azola Fali; Keith P Klugman; Anne von Gottberg
Journal:  J Clin Microbiol       Date:  2012-05-16       Impact factor: 5.948

7.  Profile of Rino Rappuoli.

Authors:  Bijal Trivedi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-10       Impact factor: 11.205

Review 8.  The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.

Authors:  Gary W Zlotnick; Thomas R Jones; Paul Liberator; Li Hao; Shannon Harris; Lisa K McNeil; Duzhang Zhu; John Perez; Joseph Eiden; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

9.  Vaccine assembly from surface proteins of Staphylococcus aureus.

Authors:  Yukiko K Stranger-Jones; Taeok Bae; Olaf Schneewind
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

10.  Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37.

Authors:  K L Seib; D Serruto; F Oriente; I Delany; J Adu-Bobie; D Veggi; B Aricò; R Rappuoli; M Pizza
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.